{"id":"fendosal","rwe":[{"pmid":"40409217","year":"2025","title":"In silico study of salicylic acid derivatives as inhibitors of Ebola proteins through molecular docking.","finding":"","journal":"Computational biology and chemistry","studyType":"Clinical Study"},{"pmid":"12152654","year":"2002","title":"Characterization and comparative evaluation of a novel PAI-1 inhibitor.","finding":"","journal":"Thrombosis and haemostasis","studyType":"Clinical Study"},{"pmid":"3872688","year":"1985","title":"The effect of food and antacid on the absorption of fendosal.","finding":"","journal":"Biopharmaceutics & drug disposition","studyType":"Clinical Study"},{"pmid":"6393076","year":"1984","title":"Analgesic effect of fendosal, ibuprofen and aspirin in postoperative oral surgery pain.","finding":"","journal":"Pharmacotherapy","studyType":"Clinical Study"},{"pmid":"6344034","year":"1983","title":"The effects of fendosal, aspirin and placebo on postoperative dental pain. A dose-ranging and efficacy study.","finding":"","journal":"Pharmacotherapy","studyType":"Clinical Study"}],"tags":[{"label":"fendosal","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Plasminogen activator inhibitor 1","category":"target"},{"label":"SERPINE1","category":"gene"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"alnovin","offLabel":[],"synonyms":["HP129","fendosal","alnovin","HP 129"],"timeline":[],"approvals":[],"brandName":"Alnovin","ecosystem":[],"mechanism":{"target":"Plasminogen activator inhibitor 1","targets":[{"gene":"SERPINE1","source":"DrugCentral","target":"Plasminogen activator inhibitor 1","protein":"Plasminogen activator inhibitor 1"}],"modality":"Small Molecule","drugClass":"fendosal","explanation":"Think of blood clots like a traffic jam in your blood vessels. PAI-1 is like a traffic cop that helps keep the clots from forming. Alnovin is like a special signal that tells the traffic cop to let the blood flow freely, reducing the risk of clots.","oneSentence":"Alnovin works by inhibiting the activity of Plasminogen activator inhibitor 1 (PAI-1), a protein that helps regulate blood clot formation.","technicalDetail":"Alnovin modulates the activity of PAI-1 through competitive inhibition, thereby increasing the availability of plasminogen activators and facilitating fibrinolysis."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3224","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=FENDOSAL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FENDOSAL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:14:53.310610","biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"fendosal","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02272049","phase":"PHASE1,PHASE2","title":"Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2014-12","conditions":["Respiratory Disorders"],"enrollment":300,"completionDate":"2029-08-31"},{"nctId":"NCT02316379","phase":"PHASE1,PHASE2","title":"Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2015-02","conditions":["Respiratory Disorders"],"enrollment":100,"completionDate":"2031-08-24"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"9Z709558TZ","CHEBI":"CHEBI:135595","INN_ID":"3965","UMLSCUI":"C0060164","ChEMBL_ID":"CHEMBL2106146","KEGG_DRUG":"D04145","PUBCHEM_CID":"40821","MESH_SUPPLEMENTAL_RECORD_UI":"C016448"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":11,"therapeuticAreas":["Hematology"],"biosimilarFilings":[],"recentPublications":[{"date":"2025 Dec","pmid":"40409217","title":"In silico study of salicylic acid derivatives as inhibitors of Ebola proteins through molecular docking.","journal":"Computational biology and chemistry"},{"date":"2002 Jul","pmid":"12152654","title":"Characterization and comparative evaluation of a novel PAI-1 inhibitor.","journal":"Thrombosis and haemostasis"},{"date":"1985 Jan-Mar","pmid":"3872688","title":"The effect of food and antacid on the absorption of fendosal.","journal":"Biopharmaceutics & drug disposition"},{"date":"1984 Nov-Dec","pmid":"6393076","title":"Analgesic effect of fendosal, ibuprofen and aspirin in postoperative oral surgery pain.","journal":"Pharmacotherapy"},{"date":"1983 Jan-Feb","pmid":"6344034","title":"The effects of fendosal, aspirin and placebo on postoperative dental pain. A dose-ranging and efficacy study.","journal":"Pharmacotherapy"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alnovin (FENDOSAL) is a small molecule drug developed to target Plasminogen activator inhibitor 1 (PAI-1), a protein involved in blood clot formation. Its exact commercial status and approved indications are unknown. As a fendosal, it is designed to modulate PAI-1 activity, potentially treating conditions related to excessive blood clotting. However, its development and approval status are unclear. Further research is needed to determine its efficacy and safety profile.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}